Hip fracture in Italy: epidemiology and preventive efficacy of bone-active drugs.
In this paper we report the results on the epidemiology of hip fracture and the preventive efficacy of bone-active drugs in Italy, observed in men and women aged 50 years or over, recruited in the three Italian centres participating in the Mediterranean Osteoporosis Study (MEDOS), namely Parma, Rome, and Siena. The number of fractures observed was 1,437 in a catchment area population of 847,508 individuals, with a total incidence of 169.6/100,000--a female-to-male ratio of 3.5 and a doubling-time of about 5.5 years. The female excess becomes evident in the age groups over 60 years. The mean age of fractures was 77 years in females and 73 in males. From the data collected, the estimated number of fractures per year in the Italian population aged over 50 years is 32,000. The pattern of use and the preventive efficacy of bone-active drugs was examined in women. Calcitonin and calcium were the drugs mainly used; less than 3% had taken vitamin D or oestrogen and only a minor percentage had taken anabolic steroids. Fluorides were not used at all. As seen in the European sample, the protective effect of calcium and calcitonin is statistically significant even in Italy, while vitamin D is not. The use of anabolic steroids was associated with a decrease in risk. Oestrogen administration does not seem to reduce the relative risk of hip fracture in Italian women, probably due to the small sample size.
Mazzuoli
G F
GF
Istituto di II Clinica Medica, Università La Sapienza, Roma, Italy.
Gennari
C
C
Passeri
M
M
Acca
M
M
Camporeale
A
A
Pioli
G
G
D000368:Aged; D000369:Aged, 80 and over; D002116:Calcitonin / Q000627:therapeutic use*; D002118:Calcium / Q000627:therapeutic use*; D017281:Cost of Illness; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006620:Hip Fractures / Q000453:epidemiology* / Q000517:prevention & control; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications*; D014807:Vitamin D / Q000627:therapeutic use
D004967:Estrogens; D014807:Vitamin D; D002116:Calcitonin; D002118:Calcium